Drugs / ReposMBZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03628079 | May 2018 → Jan 2019 | cancer of unknown primary site, digestive system cancer | Repos Pharma | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ReposMBZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03628079 ↗ |
| Route | Oral | “ReposMBZ 100 mg capsule by mouth” NCT03628079 ↗ |